key: cord-0795415-kwkgi98f
authors: Privitera, Daniele; Capsoni, Nicolò; Mazzone, Annamaria; Airoldi, Chiara; Angaroni, Laura; Pierotti, Federico; Rocca, Eugenia; Dal Molin, Alberto; Bellone, Andrea
title: Nursing evaluation during treatment with helmet CPAP in patients with respiratory failure due to COVID-19 pneumonia: A case series
date: 2021-10-23
journal: Aust Crit Care
DOI: 10.1016/j.aucc.2021.10.001
sha: 222c777819d4df4870d44357e37db35d26b0f02b
doc_id: 795415
cord_uid: kwkgi98f

BACKGROUND: During COVID-19 outbreak, with the increasing number of patients presenting with acute respiratory failure, a large use of non-invasive positive pressure ventilation was done in the emergency departments and medical wards despite the lack of recommendations. This study describes the clinical characteristics of patients presenting to the hospital with acute respiratory failure due to COVID-19 related pneumonia undergoing treatment with helmet CPAP with a strict nursing evaluation and monitoring. METHODS: A case series study enrolling adult patients admitted to an emergency department of an Italian hospital with acute respiratory failure due to COVID-19 pneumonia from March 18(th) to April 18(th), 2020, was conducted. Only patients who strictly followed a local CPAP protocol were enrolled. RESULTS: A total of 52 patients were included in this study. 38 patients (73%) were judged eligible for endotracheal intubation (ETI). Eight-teen (34.6%) were intubated. Six-teen (30.8%) patients died: 7 (38.9%) and 9 (26.5%) in the eligible and non-eligible for ETI group, respectively. The median hospital length of stay was different in ETI and non-ETI group: 26 days [IQR 16-37] vs 15 days [IQR 9-17] (p = 0.005). The median invasive mechanical ventilation time was 11 days [IQR 7-21] with an ICU length of stay of 14.5 days [IQR 10-28]. During the CPAP trial, among patients eligible for ETI variations over time for positive end-expiratory pressure (p = 0.003) and respiratory rate (p = 0.059) were found between intubated and non-intubated patients. CONCLUSIONS: A short closed monitored CPAP trial could be considered for acute respiratory failure due to COVID-19 pneumonia before considering ETI. A progressive positive end-expiratory pressure titration should target patient’s respiratory rate reduction. More studies are needed to evaluate the efficacy and predictors of failure of CPAP and non-invasive positive pressure ventilation in patients with acute respiratory failure due to COVID-19 pneumonia.

With the exponential rising of patients with Coronavirus Disease 2019 , hospitals of affected countries had to face an increasing number of patients presenting with hypoxemic respiratory failure, with a demand of mechanical support and endotracheal intubation (ETI) higher than normal, often exceeding available resources. 15% of patients with COVID-19 develop severe respiratory failure, with a rate highly dependent on patient's age and comorbidities such as obesity, diabetes mellitus, hypertension, and chronic pulmonary disease. 1 Estimated overall case fatality varies from 1.4% in patients younger than 60 years to 4.5% in those 60 years and older. 2 Patients with COVID-19 pneumonia present an atypical form of acute respiratory distress syndrome (ARDS). The first phases of the disease are characterized by a severe hypoxemia associated with a preserved lung compliance ("silent" hypoxemia). 3, 4 The severe hypoxemia is likely due to the loss of hypoxic pulmonary vasoconstriction, with a remarkable hyper perfusion of gasless tissue, and impaired regulation of pulmonary blood flow, with ventilation/perfusion (VA/Q) mismatch. Positive end-expiratory pressure (PEEP) and prone positioning can improve oxygenation through recruitment of collapsed areas and redistribution of pulmonary perfusion, improving the VA/Q ratio. In many patients the disease stabilizes at this first stage while in others, about 20-30%, it may worse to a clinical picture similar to ARDS, with bilateral CT consolidations and low compliance. 5 Evidence on non-invasive positive pressure ventilation (NIPPV) in acute respiratory failure (ARF) due to viral pneumonia is lacking and its use is still of uncertain benefit. 6, 7 Data from observational studies on the use of NIPPV in Influenza A (H1N1) viral pneumonia showed a variable successful rate between 40,7% and 48%. [8] [9] [10] Some studies reported an increased ICU mortality in patients who failed NIPPV trial compared with early invasive mechanical ventilation (IMV), whereas NIPPV success resulted in shorter hospital stay. A high rate of NIPPV failure (92,4%) was reported in critically ill patients with the Middle East Respiratory Syndrome. 1, 8, 9 Due to the lack of randomized controlled trials no recommendations are offered on NIPPV use in these patients, but according to data from observational studies, a cautious NIPPV trial in selected patients and in a protected environment and experienced centers can be tried. The application of a PEEP during ARF secondary to pneumonia has been demonstrated to improve arterial oxygenation by increasing functional residual capacity, to shift the tidal volume to a more compliant part of the pressure-volume curve and to reduce the work of breathing. 1, 8, 9 Furthermore, it recruits non-aerated alveoli in dependent pulmonary regions, stabilizes the airways, and reduces the inhomogeneity of lung volume distribution. 11 During COVID-19 spreading, NIPPV with helmet continuous positive airway pressure (CPAP) was largely used to support patients with ARF in emergency departments (EDs) and medicine wards, in order to face the large number of affected patients. A better tolerability of the helmet and a reduced room contamination compared with oronasal masks may also improve patients' clinical management, increasing the safety of healthcare workers. 12 Despite the relative simplicity of setting up a helmet CPAP, the need for attentive and careful monitoring of the respiratory and hemodynamic response to the application of PEEP should be part J o u r n a l P r e -p r o o f

This was a retrospective case series study enrolling adult patients admitted to the emergency department from March 18 th to April 18 th , 2020, with acute respiratory failure due COVID-19 pneumonia. The study was approved by the local Ethical Committee. Owing to retrospective and de-identified data collection, the need for informed consent was waived.

Patients admitted to the ED with ARF due to COVID-19 pneumonia treated with helmet CPAP, according to our operational flowchart, were included in the study. Diagnosis of COVID-19 pneumonia was made if typical CT scan patterns were present (ground-glass opacities, crazy-paving pattern, consolidations) and a SARS-CoV2 infection was confirmed by positive real-time reverse transcriptase-polymerase chain reaction assay of nasopharyngeal swab. 13

The inclusion criteria were: age 18 years or older, diagnosis of COVID-19 related pneumonia, a preserved state of consciousness 14 (Kelly Score 1 or 2) and stable hemodynamics, SpO2 level < 94% and RR ≥ 28 despite 5 L/min oxygen administration through nasal cannula or face mask. In according to the local protocol, all these patients started a trial of helmet CPAP ( Figure 1 ). Exclusion criteria were: the achievement and maintenance of a SpO2 ≥ 94% and FR < 28 with standard O2 support (5 L/min of O2 administered with nasal cannula or face mask); the need for immediate ETI for cardiovascular arrest, impaired and ineffective respiratory mechanics (e.g. agonic breathing and thoracic-abdominal dyskinesia); hemodynamic instability or severe arrhythmias; altered state of consciousness (Kelly score ≥ 3); contraindications to CPAP (severe bleeding of the upper digestive tract, vomiting, inability to protect the airways; recent surgery on the skull or esophagus; trauma and cranio-facial burns; undrained pneumothorax). Patients with symptoms and radiological imaging suggestive for COVID-19 pneumonia but no microbiological confirmation were also excluded. All patients were followed up to from the day of hospital admission to the day of hospital discharge or death.

CPAP was delivered through helmet and high flow generating devices as first choice. According to the local operative flowchart initial settings were a PEEP of 7,5 cm/H20, a Flow ≥ 60 L/min and a FiO2 titrated to reach a SpO2 ≥ 94% and a RR ≤ 25 bpm. PEEP was increase by 2.5 cm/H2O up to a maximum of 12.5 cm/H2O in case of failure to reach the RR established target. The CPAP trial lasted 120 minutes ( Figure 1) . Alternatively, in patients with risk of muscular J o u r n a l P r e -p r o o f exhaustion (e.g., history of Chronic Obstructive Pulmonary Disease, neuromuscular disease) a trial of Bi-PAP was started with a face mask. 15 If a SpO2 ≥ 94% and a RR  25 min were reached after the 120-minute trial, CPAP treatment was continued alternating with high-flow nasal cannula, maintaining continuous vital signs monitoring. In case of failure to reach the established targets after 120 minutes of CPAP trial, patients were evaluated for early ETI if candidates for ICU. In patients with a Do-Not-Intubate (DNI) order, the choice to continue helmet CPAP or shift to standard O2 therapy and start palliative care depended on clinician evaluation. 15

Demographics, comorbidities, time from symptoms onset, arterial blood gases, clinical and laboratory findings on admission were recorded. SpO2, RR and body temperature were recorded before CPAP trial was started and then every 30 minutes together with PEEP and FiO2 used until the end of the trial (t0 -t30 -t60 -t90 -t120). ETI was performed according to clinical judgment of ICU specialist. Patients not considered eligible for ETI due to their age and comorbidity and the severity of the disease, received a DNI order after the evaluation of an ICU specialist in agreement with the emergency physician. Data on time from the beginning of CPAP trial to ETI together with data on duration of NIPPV (intended as cycles of CPAP or Bi-PAP longer than 6 hours for day) or of IMV were collected. Pharmacological treatment was recorded too.

No statistical sample size calculation was performed a priori, and sample size was equal to the number of patients treated with helmet CPAP during the study period. Socio-demographic variables and clinical data were reported as absolute and relative frequencies for categorical variables, while for numerical ones the mean and the corresponding standard deviation (SD) or median and interquartile range (IQR) were reported, as appropriate. Percentage of subjects who needed invasive mechanical ventilation and died were calculated with their 95% confidence interval (95% CI). To explore the risk factors associated with ETI, the χ² test or Fisher's exact test and the student or Mann-Whitney U test were used to compare the socio demographic and clinical variables with the use of IMV. To better understand the time trend of parameters related to the use of CPAP (FiO2, PEEP, RR, SpO2), graphical representations were done using mixed models, which take into account for repeated measures within subjects. The same models, adding as covariate the use of ETI, were also performed to evaluate if significant changes between groups were observed. Survival curves were plotted using the Kaplan-Meier method and compared between patients with vs without ETI using the log-rank test. A two-sided α of less than 0.05 was considered statistically significant. Statistical analyses were done using the SAS software (version 9.4).

In the period from 18 March 2020 to 18 April 2020, a total of 52 patients met the study inclusion criteria. The median age was 62.5 years (IQR, 50-72.50 years) and 40 were male (76.9%). The most commonly self-reported symptoms at illness onset were fever followed by dyspnea and cough. Thirty-eight (73%) patients had at least one comorbidity, with hypertension, obesity, and cardiomyopathy being the most prevalent. The median waiting time from the first ED evaluation to the beginning of CPAP treatment was 118 minutes with minimum of 9 minutes to maximum of 911 minutes. 11 subjects (21.15%) received morphine in the first two hours of CPAP trial.

Thirty-eight (73%) were judged eligible for ETI, of which 18 were intubated (34.62%; 95% CI 21.68-47.55) (Figure 2 ).

No differences in demographics, clinical features and laboratory findings were found between subjects undergoing ETI compared to the others, except for P/F ratio (103 vs 214, p = 0,03) ( Table 1) . For these 18 patients the median time lapse between hospital admission and ETI was 2 days [IQR 1-6] with a range from a minimum of 1 to a maximum of 30 days.

The CPAP-related parameters (PEEP, FiO2, RR and SpO2) and their variation over time analyzed for patients eligible for ETI, are shown in figure 3 . Considering the models with ETI as covariate, changes between the two groups were found for PEEP (p = 0.003) and RR (p = 0.059). No significant changes were found for FiO2 (p = 0.245) and SpO2 (p = 0.076).

A total of 16 (30.8%; 95% CI 18.22-43.31%) subjects died: 7 (38.9%) and 9 (26.5%) in the eligible for ETI and noneligible for ETI group, respectively. Considering only patients eligible to ETI, ETI patients had significant higher mortality rate compared to the others (N=7, 38.9% vs N=0; p = 0.002).

The median length of stay in hospital was different in subjects with and without ETI: 26 days [IQR vs 15 days respectively (p = 0.005). The median CPAP time was 4.50 days [1] [2] [3] [4] [5] [6] [7] , ranging from 1 to 14 days. The median IMV time was 11 days with an ICU length of stay of 14.5 days [IQR 10-28].

J o u r n a l P r e -p r o o f DISCUSSION To our knowledge, this is the first reported case series study of patients with ARF due to COVID-19 describing a strict nursing evaluation and monitoring during a standardized CPAP trial in the ED and subsequent patient's outcomes.

Fifty-two patients were included in the study. The population enrolled was similar in terms of comorbidities and clinical features to other studies populations of COVID-19 patients described in literature. 1, 16 Median time from symptoms onset and hospital admission was 7 day [IQR [5] [6] [7] [8] [9] [10] whereas only 1 [0-3] from dyspnea onset. Delayed hospital presentation was in part due to the attempt to manage patients at home. The late appearance of dyspnea might be due to the typical normal pulmonary compliance in the first phases of the disease and the initial "silent hypoxia". [3] [4] All patients had severe or moderate ARF and most of them started CPAP treatment within 3 hours from hospital admission; few of them started it later due to progressive worsening of respiratory failure during ED observation. 73% were eligible for ETI. The ETI rate was 34,6%, concordant to other case series even if still few data on NIPPV failure in these patients are available. 17 Patients who were intubated had a significant lower P/F ratio compared to those treated only with NIPPV. ETI was performed with a median time lapse of 2 days. When it was not performed immediately after the CPAP trial, the delay was never due to the CPAP treatment prolongation but to a subsequent worsening of respiratory failure or to a lack of resources available. General mortality was 30,7% with not significant differences between ETI and non-ETI patients. All patients eligible to ETI but treated only with CPAP survived. The mortality rate was similar to other studies populations even if a comparison is not easy due to differences in disease severity among different studies groups. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] A significant difference in the median length of hospital stay hospital resulted between ETI and non-ETI patients, 26 days [IQR vs 15 days respectively (p = 0.005), certainly due, in addition to initial patients' severity, to complications related to IMV and ICUs stay. We decided to evaluate CPAP-related parameters and their variation on time only in patients eligible to ETI to assess whether an early RR improvement with a step-up PEEP titration could be useful in identifying PEEP responder patients treatable without IMV. Patients with an early respiratory rate improvement likely have a prevalent hypoxic stimulus on respiratory drive, which is reduced by correcting hypoxia through alveolar recruitment and oxygenation. We found that non-ETI patients, while using lower mean PEEPs, had a sharper and faster decline in RR after starting the CPAP trial. We think that a nursing evaluation and close monitoring of respiratory parameters, in particular RR, should be done when a CPAP trial is started, to identify patients likely to respond to CPAP treatment. Our study has some limitations due to its retrospective and single-center study design. The results must be considered cautiously due to the small sample of patients evaluated. On the other hand, its strength and novelty lie on the application of a local protocol for the use of helmet CPAP to treat COVID 19 patients and a strict nursing evaluation and monitoring in the first hours of CPAP treatment. We standardized the initial approach to COVID-19 patients presenting with ARF to the ED, proposing a progressive up titration of PEEP to increase SpO2 and lower RR. 

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Estimates of the severity of coronavirus disease 2019: a model-based analysis

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Management of COVID-19 Respiratory Distress

COVID-19 pneumonia: ARDS or not?

Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

Critical care management of adults with community-acquired severe respiratory viral infection

Early non-invasive ventilation treatment for severe influenza pneumonia

Risk Factors for Noninvasive Ventilation Failure in Critically Ill Subjects With Confirmed Influenza Infection

Effectiveness and predictors of success of noninvasive ventilation from a northern Italy Emergency Department

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Is continuous positive airway pressure (CPAP) a new standard of care for type 1 respiratory failure in COVID-19 patients? A retrospective observational study of a dedicated COVID-19 CPAP service

Figure 2: Respiratory rate, PEEP, SpO2 and FiO2 values over time in endotracheal intubation (ETI, solid line) and non-ETI patients

Abbreviations: ETI: endotracheal intubation; PEEP: positive end-expiratory pressure; FiO2, fraction of inspired oxygen

Peripheral oxygen saturation

Number (%)

Protein, g/dL, Mean (DS)

Creatinine, mg/dL, Mean (DS)

Total bilirubin, mg/dL, Mean (DS)